Onyx Biotec Ltd IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| QIB | — | 2,278,000 (47%) | — | ₹1,390 Cr |
| NII (HNI) | — | 688,000 (14%) | — | ₹420 Cr |
| Retail | — | 1,600,000 (33%) | — | ₹976 Cr |
| Market Maker | — | 244,000 (5%) | — | ₹15 Cr |
| Σ Total | — | 4,810,000 (100%) | — | ₹29,341 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 2,000 | ₹122,000 |
| Retail (Max) | 13 | 26,000 | ₹1,586,000 |
| S-HNI (Min) | 14 | 28,000 | ₹1,708,000 |
| B-HNI (Min) | 67 | 134,000 | ₹8,174,000 |
Financial Statements Amount in ₹ Lakhs
| Metric | 31 May 2024 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Revenue | 1,054 | 5,387 | 3,962 |
| Profit After Tax | 131 | 303 | 184 |
| Net Worth | 2,619 | 2,488 | 1,820 |
| Total Assets | 7,477 | 7,414 | 5,872 |
| Reserves & Surplus | 1,286 | 1,156 | 1,230 |
| Total Borrowing | 3,156 | 3,078 | 2,923 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use –
- Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections; –
- Prepayment or repayment of all or a portion of certain loans availed by the Company; and –
- General Corporate Purposes. –
Company Overview
Incorporated in May 2005, Onyx Biotec Limited is a pharmaceutical company providing sterile water for injections. The company currently manufactures Sterile Water for Injections and serves as a pharmaceutical contract manufacturer, offering a comprehensive range of Dry Powder Injections and Dry Syrups for both the Indian and overseas markets.
The company has two manufacturing units in Solan, Himachal Pradesh. Unit I has a daily production capacity of 638,889 units of Sterile Water for Injections, while Unit II produces 40,000 units of dry powder injections and 26,667 units of dry syrup per day in a single shift.
The company clientele includes Hetero Healthcare Limited, Mankind Pharma Limited, Sun Pharmaceutical Industries Limited, Aristo Pharmaceuticals Private Limited, Macleods Pharmaceuticals Limited, Mapra Laboratories Private Limited, Axa Parenterals Limited, FDC Limited, Zuventus Healthcare Limited, Akums Drugs and Pharmaceuticals Limited, Reliance Life Sciences Limited, among others.
As of May 31, 2024, the company had a client base of more than 100 Indian and multinational pharmaceutical companies.
The company has received certificates for the management system, ISO 9001:2015, and ISO 14001:2015 from ROHS Certification Private Limited.
As of July 31, 2024, the company has 175 employees across various departments.